A new drug developed to treat the iron overload resulting from thalassemia major fails to do
so adequately and may even worsen hepatic fibrosis caused by iron, a study has concluded …

A new drug developed to treat the iron overload resulting from thalassemia major fails to do
so adequately and may even worsen hepatic fibrosis caused by iron, a study has concluded …

Background Deferiprone is an orally active iron-chelation agent that is being evaluated as a
treatment for iron overload in thalassemia major. Studies in an animal model showed that …

Background: Pediatric thalassemia major (TM) patients may begin lifelong iron chelation
therapy (ICT) as early as 2 years to avoid potential complications of iron overload, such as …

The role of the orally active iron (Fe) chelator deferiprone in the treatment of β-thalassemia
remains a controversial subject. Despite initial studies showing high Fe chelation efficacy in …

Objective To assess the efficacy of deferasirox as an iron chelator, with specific reference to
reducing cardiac iron overload. Design Prospective, open label, single arm study between …

Over the last 20 years, management for thalassemia major has improved to the point where
we predict that patients' life expectancy will approach that of the normal population. These …

Data suggest a large variability in the effectiveness of the orally active iron chelator,
deferiprone, in inducing a sustained decrease in body iron to concentrations compatible with …

Abstract Abstract 5294 Background: Deferasirox is a relatively new once-daily oral iron
chelator widely used for patients with thalassemia major. Efficacy of deferasirox has been …

Patients with β-thalassemia require lifelong iron chelation therapy from early childhood to
prevent complications associated with transfusional iron overload. To evaluate long-term …